-- 13-Month Data Show Efficacy and Durability of Protein Expression following a Single Intravitreal Administration of ADVM-022 -- -- Data to be Presented in a Poster Session on May 17, 2018 at the ASGCT 21st Annual Conference -- MENLO PARK, Calif., May 01, 2018...

MENLO PARK, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today reported financial results for the fourth quarter ended...

-- Data Monitoring Committee Recommends Proceeding to the Second Cohort -- -- Company Expects to Report Preliminary Data in the Second Half of 2018 -- MENLO PARK, Calif., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage...

MENLO PARK, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the closing of its previously announced...

MENLO PARK, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the pricing of an underwritten public offering...

MENLO PARK, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced that it has commenced an underwritten public...

Companies Exploring the Delivery of Genome Editing Medicines to the Eye MENLO PARK, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular...

Accelerating Pipeline Development in 2018 after Transforming into Clinical-stage Company in 2017 MENLO PARK, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in...

-- Company Expects to Report Preliminary Data in the Second Half of 2018 -- MENLO PARK, Calif., Dec. 28, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and...

-- Patients to Receive Single-administration of Gene Therapy Candidate ADVM-043 ---- Company Expects to Report Preliminary Data in the Second Half of 2018 -- MENLO PARK, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a leading...